• Eswar Krishnan, Kasem S Akhras, Hari Sharma, Maryna Marynchenko, Eric Wu, Rima H Tawk, Jinan Liu, and Lizheng Shi.
• Stanford University, Stanford, California; Takeda Pharmaceuticals International Inc., Deerfield, Illinois, USA.
• J Rheumatol. 2013 Jul 1; 40 (7): 1166-72.

ObjectiveTo study the association between serum urate level (sUA) and the risk of incident kidney disease among US veterans with gouty arthritis.MethodsFrom 2002 through 2011 adult male patients with gout who were free of kidney disease were identified in the data from the Veterans Administration VISN 16 database and were followed until incidence of kidney disease, death, or the last available observation. Accumulated hazard curves for time to kidney disease were estimated for patients with average sUA levels > 7 mg/dl (high) versus ≤ 7 mg/dl (low) based on Kaplan-Meier analyses; and statistical comparison was conducted using a log-rank test. A Cox proportional hazard model with time-varying covariates was used to estimate the unadjusted and adjusted hazard ratios for kidney disease.ResultsEligible patients (n = 2116) were mostly white (53%), with average age 62.6 years, mean body mass index 31.2 kg/m(2), and high baseline prevalence of hypertension (93%), hyperlipidemia (67%), and diabetes (20%). Mean followup time was 6.5 years. The estimated rates of all incident kidney disease in the overall low versus high sUA groups were 2% versus 4% at Year 1, 3% versus 6% at Year 2, and 5% versus 9% at Year 3, respectively (p < 0.0001). After adjustment, high sUA continued to predict a significantly higher risk of kidney disease development (HR 1.43, 95% CI 1.20-1.70).ConclusionMale veterans with gout and sUA levels > 7 mg/dl had an increased incidence of kidney disease.

22 keywords...

hide…